New Drug Doubles Pancreatic Cancer Survival Rates

A breakthrough drug targeting previously "undruggable" KRAS mutations has approximately doubled survival time for metastatic pancreatic cancer patients compared to chemotherapy.

The development marks a historic shift for a disease that affects over 90% of pancreatic cancer cases.